Bristol Myers Squibb acquires Orbital Therapeutics
Client(s) Bristol Myers Squibb
Jones Day acted as Tax counsel to Bristol Myers Squibb in its $1.5 billion acquisition of Orbital Therapeutics, a privately held biotechnology company pioneering a new generation of RNA medicines that reprogram the immune system in vivo, enabling treatments that provide the precision, control, and flexibility needed to address the underlying biology and unique complexities of each disease.
